Latest Breaking News On - Joop de langen - Page 1 : comparemela.com

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

Noord hollandNatalia isabel valdiviezo lamaNetherlands cancer instituteDrug administrationNational institute of neoplastic diseasesEuropean lung cancer congressNational instituteNeoplastic diseasesMedscape medical newsJoop de langenNon small cell lung cancerLung cancerUng carcinomaAncer of the lungBiologic therapyTyrosine kinase inhibitor